Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Inclusion Criteria: Patients who meet all of the following criteria are eligible for the study: * Aged ≥6 years at the time of screening * VWD type 1 (baseline von Willebrand factor activity \[VWF:Ristocetin Co-factor (RCo)\] \<30 IU/dL, 2A, 2B, 2M, or 3 according to medical history requiring substitution therapy with a VWF-containing product to control bleeding * Currently receiving on-demand treatment with a VWF-containing product with at least 1, and an average of ≥2, documented spontaneous BEs per month in the last 6 months, with at least 2 of these BEs requiring treatment with a VWF-containing product * Availability of records to reliably evaluate type, frequency, and treatment of BEs for at least 6 months of on-demand treatment before screening * Female patients of child-bearing potential must have a negative urine pregnancy test at screening and agree to use adequate birth control measures; in case hormonal contra-ception is used, the medication class should remain unchanged for the duration of the study * All patients to provide voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted Exclusion Criteria: Patients who meet any of the following criteria are not eligible for the study: * Having received on-demand or prophylactic treatment with a VWF-containing product but having no records available to reliably evaluate the type, frequency, and treatment of BEs over a period of at least 6 months of on-demand treatment * History, or current suspicion, of VWF or FVIII inhibitors * Medical history of a thromboembolic event within 1 year before enrolment * Severe liver or kidney diseases (alanine aminotransferase \[ALAT\] and aspartate trans-aminase \[ASAT\] levels \>5 times of upper limit of normal, creatinine \>120 µmol/L) * Platelet count \<100,000/µL at screening (except for VWD type 2B) * Body weight \<20 kg at screening * Patients receiving, or scheduled to receive, immunosuppressant drugs (other than an-tiretroviral chemotherapy), such as prednisone (equivalent to \>10 mg/day), or similar drugs * Pregnant or breast-feeding at the time of enrolment * Cervical or uterine conditions causing abnormal uterine bleeding (including infection, dysplasia) * Treatment with any IMP in another interventional clinical study currently or within 4 weeks before enrolment * Other coagulation disorders or bleeding disorders due to anatomical reasons * Known hypersensitivity to any of the components of the study drug